RELIEF-DPN-1 clinical trial : Lexicon begins patient dosing with LX9211
RELIEF-DPN-1 clinical trial : Lexicon Pharmaceuticals has started patient dosing in a phase 2 trial of LX9211 for the treatment of diabetic peripheral neuropathic pain. According to the Texan biopharma company, LX9211 is an oral small molecule inhibitor of adaptor associated kinase 1 (AAK1). The RELIEF-DPN-1 clinical trial is a randomized, placebo-controlled, multi-center clinical study […]